期刊文献+

艾塞那肽联合胰岛素泵治疗2例1型糖尿病的临床观察 被引量:5

原文传递
导出
摘要 胰岛素治疗是l型糖尿病的基础治疗,然而单用胰岛素治疗1型糖尿病有时不能使血糖达标,低血糖和餐后高血糖往往是治疗中的难点。胰高血糖素样肽-1(GLP-1)具有葡萄糖依赖性的调节血糖作用,而艾塞那肽作为首个应用于临床的GLP-1类似物,其适应证为2型糖尿病。国外有个别研究性报告将艾塞那肽应用于1型糖尿病,而国内尚未见报道。近期我们对2例血糖持续增高、血糖波动较大难以控制的1型糖尿病患者予艾塞那肽联合胰岛素泵治疗,取得良好效果,现报告如下。
出处 《中华糖尿病杂志》 CAS CSCD 2013年第2期122-124,共3页 CHINESE JOURNAL OF DIABETES MELLITUS
基金 国家自然科学基金(30771031) 国家高技术研究发展计划(893)课题(2012AA02A509) 国家重点基础研究计划(973)课题(2011CB504001) 北京市科技计划课题(D09050704610012)
  • 相关文献

参考文献26

  • 1Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes : potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther, 2002,4 : 175-189.
  • 2Flint A, Raben A, Astmp A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest, 1998,101:515-520.
  • 3Farilla L, Hui H, Bertolotto C, et al. Glueagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology ,2002,143:4397-4408.
  • 4Perfetti R, Zhou J, Doyle ME, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology, 2000, 141: 4600-4605.
  • 5Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia, 2002,45 : 1263-1273.
  • 6Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta- cell mass and improved glucose tolerance in diabetic rats. Diabetes, 1999,48:2270-2276.
  • 7Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology, 2003, 144: 5149- 5158.
  • 8Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology,2005,146:2069-2076.
  • 9Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP- 1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab, 2002, 283:745-752.
  • 10Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol,2003, 140 : 123-132.

同被引文献69

  • 1李显丽,李奕平,王晓苓.艾塞那肽治疗肥胖2型糖尿病的临床疗效观察[J].昆明医科大学学报,2012,33(4):125-127. 被引量:4
  • 2常海庆.国外四大综合类医学期刊的规模扩张与启示[J].医疗保健器具,2007,14(4):36-38. 被引量:2
  • 3中华医学会糖尿病学分会.中国1型糖尿病诊治指南[M].北京:人民卫生出版社,2012:11-15.
  • 4Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and centralnervous system[J]. Endocrinology,2004,145 (6) :2653- 2659.
  • 5Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin4 and glucagon-like peptide-1 in vivo and in vitro [ J ]. Metabolism,2001,50(5) :583-589.
  • 6Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double- blind, placebo-controlled, parallel-group study [ J ]. Clin Ther, 2008 ,30 ( 8 ) : 1448-1460.
  • 7Norris SL, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review [ J ]. Diabet Med, 2009 ,-26 ( 9 ) : 837- 846.
  • 8DeFronzo RA, Triplitt C, Qu Y, et al. Effects of exenatide plus rosiglitazone on 13-Cell function and insulin sensitivity in subjects with type 2 diabetes on mefformin [ J ]. Diabetes Care, 2010,33 (5) :951-957.
  • 9Traina AN, Lull ME, Hui AC, et al. Once-weekly exenatide as adjunct Ireatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy [ J ]. Can J Diabetes,2014,38 (4) :269-272.
  • 10Fu Z, Kuang HY, Hao M, et al. Protection of exenatide for retinal ganglion cells with different glucose concentrations [ J ]. Peptides,2012,37 ( 1 ) :25-31.

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部